Youn Kyung
Youn Kyung Houh, Seoul KR
Patent application number | Description | Published |
---|---|---|
20130217635 | NOVEL USE OF ERYTHROID DIFFERENTIATION REGULATOR 1 AS AN AGENT FOR TREATING CANCER - The present invention relates to a novel use of erythroid differentiation regulator 1 (Erdr1) as an agent for treating cancer. More particularly, it relates to an use of Erdr1 or an expression vector including a polynucleotide encoding the same for preventing and inhibiting cancer metastasis, an use of Erdr1 or an expression vector including a polynucleotide encoding the same for preventing and treating cancer, an use of an antibody specific for Erdr1 for diagnosing cancer, or a method for screening agents for regulating cancer metastasis or cancer cells migration. The Erdr1 is negatively regulated by IL-18 expression and it suppresses migration, invasion and metastasis of cancer or tumor cell by expression of HSP90 and generation of ROI. And an Erdr1 recombinant protein promotes NK-cell killing activity against cancer cell. Accordingly, the Erdr1 and an expression vector comprising polynucleotide encoding the same and recombinant protein suppress cancer metastasis and bring an effect on activation of immune cells, and therefore can be useful for preventing, treating and diagnosing cancer. | 08-22-2013 |
Youn Kyung Kim, Daejeon KR
Patent application number | Description | Published |
---|---|---|
20130088285 | DC VOLTAGE CONVERSION CIRCUIT OF LIQUID CRYSTAL DISPLAY APPARATUS - Disclosed is a DC voltage conversion circuit of a liquid crystal display apparatus, including: a main pumping circuit including a plurality of thin film transistors and configured to output voltage for driving a liquid crystal display apparatus when the plurality of thin film transistors are alternately turned on or off; and a switch control signal generator configured to control voltages applied to gates of the plurality of thin film transistors by inversion of a clock signal, in which each thin film transistor is turned on when positive gate-source voltage is applied thereto, and turned off when negative gate-source voltage is applied thereto. | 04-11-2013 |
Youn Kyung Ko, Daejeon KR
Patent application number | Description | Published |
---|---|---|
20140199303 | Stable Liquid Formulation of Etanercept - The present invention relates to a stable liquid formulation of etanercept (recombinant p75 sTNFR:Fc fusion protein), and more particularly, to a liquid formulation comprising one or more stabilizers selected from the group consisting of methionine, lysine, histidine, and pharmaceutically acceptable salts thereof in an amount sufficient to reduce by-product formation of etanercept during storage. The liquid formulation according to the present invention effectively reduces production of etanercept by-products and to stably maintain its pharmaceutical efficacies for long-term storage. Therefore, the reconstitution procedure is not required before administration, and the sterile formulation can be administered to patients to ensure patient safety. Thus, it can be applied to the fields in need of etanercept treatment. | 07-17-2014 |